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ABSTRACT
Stromal-tumor interactions in pancreatic cancer (PC) impact on treatment 
outcomes.  Pancreatic stellate cells (PSCs) produce the collagenous stroma of PC and 
interact with cancer cells to facilitate disease progression. A candidate growth factor 
pathway that may mediate this interaction is the hepatocyte growth factor (HGF)/
c-MET pathway. HGF is produced by PSCs and its receptor c-MET is expressed on 
pancreatic cancer cells. We studied the effects on PC progression of inhibiting the HGF/
c-MET pathway in the presence and absence of a representative chemotherapeutic 
agent, gemcitabine. Using an orthotopic model of PC we have shown that “triple 
therapy” (inhibition of both HGF and c-MET combined with gemcitabine) resulted in 
the greatest reduction in tumor volume compared to each of the treatments alone or in 
dual combinations. Importantly, metastasis was virtually eliminated in mice receiving 
triple therapy. Our in vivo findings were supported by in vitro studies showing that 
the increase in cancer cell proliferation and migration in response to PSC secretions 
was significantly inhibited by the triple regimen.  Our studies suggest that a combined 
approach, that targets tumor cells by chemotherapy while inhibiting specific pathways 
that mediate stromal-tumor interactions, may represent a novel therapeutic strategy 
to improve outcomes in PC.
INTRODUCTION
Around 338000 new cases of pancreatic cancer (PC) 
are diagnosed worldwide each year and this devastating 
disease is set to become the second leading cause of cancer 
related deaths in the next decade [1]. Thus, there is an 
urgent need to develop new therapies to tackle this disease. 
PC is characterized by pronounced desmoplasia or dense 
collagenous stroma, which is now well acknowledged to 
have an intrinsic role in PC progression [2–4]. Our Group 
has demonstrated that this collagenous stroma is produced 
by activated pancreatic stellate cells (PSCs) [5]. Several 
preclinical studies have reported a close bidirectional 
interaction between pancreatic cancer cells and PSCs [6–10] 
which facilitates pancreatic cancer progression as evidenced 
by increased tumor growth as well as metastasis [7, 10–15]. 
Identifying the factors mediating the observed 
interaction between PSCs and PC cells may provide 
insights into novel therapeutic targets in PC [3, 15]. 
A candidate factor that has received some attention in 
recent years is the hepatocyte growth factor (HGF), which 
has been shown to have a role in the progression of PC [16, 
17], particularly with respect to stromal-tumor interactions 
[14, 18]. We have demonstrated that HGF is secreted by 
cancer-associated human PSCs (hPSCs) [14, 19]. Binding 
of HGF to its transmembrane cell surface receptor c-MET, 
which is expressed on cancer cells activates several 
intracellular cell-signalling pathways that play a pivotal 
role in cancer cell proliferation and migration. We have 
also demonstrated that c-MET is present on the surface 
of endothelial cells, which potentiate PSC-endothelial cell 
interaction thus indicating a role in angiogenesis, and a 
consequent influence on metastatic spread [19]. HGF/c-
MET binding has been reported to stimulate further 
production of HGF by mesenchymal cells, resulting in 
the formation of a feed-forward loop [20, 21]. Our recent 
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work has shown that this pathway plays a critical role in 
cancer cell and endothelial cell functions [14, 19].
Using an orthotopic model of PC produced 
by injecting a mixture of cancer cells and cancer-
associated human PSCs (hPSCs) into mouse pancreas 
[14], we recently published the effects of HGF 
inhibition (using a specific neutralizing antibody 
AMG102) and a representative chemotherapeutic agent, 
gemcitabine, as single agents and in combination, on PC 
progression. Effect of HGF inhibition was equivalent 
to gemcitabine in reduction of tumor volume but had 
a significantly greater effect on reducing metastasis. 
Indeed, gemcitabine alone failed to prevent metastasis, 
paralleling the clinical experience of patients receiving 
adjuvant gemcitabine developing metastases during 
treatment. We also observed that when gemcitabine 
was combined with HGF inhibition, the anti-metastatic 
effect of the latter was lost [14]. This may be a 
consequence of a gemcitabine-induced predisposition to 
increased stemness and aggressiveness of cancer cells, 
as has been shown by several other previous studies 
[14, 22–25]. However, another possible reason is that 
modulating only one arm (i.e. HGF) of the HGF/c-MET 
pathway, may not be sufficient to achieve an optimal 
anti-metastatic response.
In view of the above, it was of interest to 
determine the effects on PC of targeting both the ligand 
and its receptor (HGF and c-MET respectively), in the 
presence and absence of gemcitabine. The aim of the 
current studies was to determine the effects of i) HGF 
neutralizing antibody AMG102, ii) a small molecule 
inhibitor for c-MET (Compound-A) and iii) the 
chemotherapeutic agent gemcitabine, alone or in dual 
and triple combinations on PC progression, using both in 
vivo and in vitro approaches. 
RESULTS
In vivo studies
Effect of HGF/c-MET inhibition ± gemcitabine on 
tumor volume
AMG102, compound-A, and gemcitabine as single 
agents significantly inhibited tumor growth when compared 
with IgG treated animals (Figure 1). Confirming our 
previously published results, HGF inhibition was as effective 
as gemcitabine in reducing tumor volumes in our model. 
Dual treatments did not exert any additive or synergistic 
effects on tumor volume reduction compared to single agents. 
However, the greatest reduction in tumor volume (to 17.9 ± 
2.2 % of control mice receiving IgG treatment) was seen in 
the group of mice that received triple therapy (HGF inhibition 
+ c-MET inhibition + gemcitabine).
Effect of HGF/c-MET inhibition ± gemcitabine 
on tumor metastasis
Mice treated with AMG102 or Compound-A 
as single agents and in dual combinations exhibited 
significantly reduced metastasis when compared to mice 
receiving IgG (Figure 2 and Table 1). Mice treated with 
gemcitabine as a single agent or in combination with 
AMG102 or Compound-A displayed some reduction in 
metastasis but this change was not statistically significant 
when compared to IgG treated mice. In contrast, in mice 
receiving triple therapy, there was a virtual elimination of 
metastasis with only one mouse in the group displaying 
a solitary metastatic nodule in the liver (Figure 2 and 
Table 1). Metastatic score was calculated as number of 
visible nodules per site (liver kidney, retroperitoneum, 
Figure 1: Effect of treatments on pancreatic tumor volumes. Pancreatic tumor volumes were reduced to a similar extent by 
AMG102, compound-A and gemcitabine, whether administered as single agents or in dual combinations, compared to tumors in IgG 
treated (control) animals (*p < 0.005 vs IgG; n = 7/group). However, the greatest reduction of tumor volume was observed in mice treated 
with triple therapy (§p < 0.05 vs G; **p < 0.0001 vs IgG; n = 7/group). Study Groups: Control group (IgG/vehicle control). AMG102 - A, 
Compound-A (small molecule c-MET inhibitor)- C, Gemcitabine - G, AMG102 + Compound-A (A+C), AMG102 + gemcitabine (A+G), 
c-MET inhibitor + gemcitabine (C+G), AMG102 + c-MET inhibitor + gemcitabine (Triple therapy or CAG).
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bowel and diaphragm) x number of mice and expressed as 
% of control score in IgG treated mice.
Histological characterization of primary tumors
Effect of treatments on cancer cell numbers
Morphometric analysis of tumor sections 
immunostained for cytokeratin allowed calculation of cancer 
cell density in tumors from each treatment group (expressed 
as number of cytokeratin positive cells/mm2).  AMG102 and 
Compound-A treatments both as single agents as well as in 
dual combinations did not result in reduction of cytokeratin 
expression compared to IgG treated tumors (Figure 3). 
However, Gemcitabine alone or in combination with 
AMG102 or compound-A significantly reduced cytokeratin 
positive cells compared to IgG treated tumors (Figure 3). Mice 
treated with triple therapy exhibited a reduction in cancer cell 
numbers to a similar extent as gemcitabine treated groups and 
to a significantly less extent than in control mice (IgG treated 
mice). This effect is not unexpected given the cytotoxic effect 
of gemcitabine on cancer cells in these tumors.
Effect of treatments on collagen deposition
The effect of treatments on fibrosis was assessed by 
software-assisted morphometric analysis on sections stained 
for Sirius red (which stains fibrillar collagen). AMG102 
treatment alone did not change collagen deposition. Tumors 
from mice, which received AMG102+gemcitabine exhibited 
significantly higher Sirius Red expression than IgG treated 
mice (Figure 4). Tumors from mice treated with gemcitabine 
alone, and in combination with compound-A and with triple 
therapy also showed an increasing trend to higher Sirius red 
expression than IgG control mice but these increases did not 
reach statistical significance. 
Effect of treatments on cancer stem cell and EMT 
markers in vivo
The paradoxical lack of an anti-metastatic effect 
with gemcitabine treatment both as a single agent and in 
dual combination with HGF or c-MET inhibitor (Figure 2) 
suggested that gemcitabine treatment may be selecting out a 
sub-population of cancer cells, possible stem-like cells with 
an aggressive phenotype and increased migratory potential 
due to an increase in epithelial-mesenchymal transition 
(EMT) as occurred with our previous studies [14].
i) Stem cell marker:
Immunohistochemistry of primary tumor sections 
for the stem cell marker (DCLK1) demonstrated that 
tumors from mice treated with gemcitabine alone, or in 
dual combinations with either AMG102 or compound-A 
exhibited higher expression of DCLK1 (Figure 5). 
However, gemcitabine in combination with HGF+c-
MET inhibition (triple therapy) resulted in a significant 
reduction in DCLK1 expression back to control levels. 
ii) EMT marker:
Immunohistochemistry of primary tumor sections for 
the EMT marker (TWIST) demonstrated that tumors from 
mice treated with gemcitabine alone, or in combination 
with AMG102 exhibited significantly higher expression of 
TWIST compared to IgG treated control mice (Figure 6A). 
Although the mice receiving gemcitabine in combination 
with compound-A (C+G) as well as mice in the triple 
therapy groups demonstrated a trend to an increase in 
TWIST expression, this did not reach statistical significance. 
Immunoblotting tumor homogenates for e-cadherin showed 
a trend to a reduction in e-cadherin expression in tumors 
from mice treated with gemcitabine. This reduction was 
Figure 2: Effect of treatments on metastatic spread. Mice treated with AMG102 and Compound-A (both as single agents and 
in combination) exhibited significantly reduced metastatic spread to the organs/regions depicted in the Table 1 when compared to IgG 
treated mice. In contrast, decrease in metastasis was not statistically significant in mice treated with gemcitabine as single agent or in dual 
combinations. Interestingly, mice treated with triple therapy exhibited virtual absence of metastasis. (*p < 0.05; §p < 0.001 vs IgG, n = 7/
group). Study Groups: Control group (IgG/vehicle control). AMG102 - A, Compound-A (small molecule c-MET inhibitor)- C, Gemcitabine 
- G, AMG102 + Compound-A (A+C), AMG102 + gemcitabine (A+G), c-MET inhibitor + gemcitabine (C+G), AMG102 + c-MET inhibitor 
+ gemcitabine (Triple therapy or CAG).
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statistically significant in tumors from C+G group when 
compared with tumors from triple therapy group (Figure 6B).
Effect of treatments on tumor angiogenesis in vivo
As HGF is known to have an angiogenic effect 
in several other cancers [26, 27], tumor sections were 
stained for the endothelial cell marker CD31, an indicator 
of neo-angiogenesis. Morphometric analysis of stained 
sections indicated a modest but statistically significant 
decrease in CD31 expression in tumors from mice treated 
with AMG102 compared to IgG treated tumors (82.63 ± 
4.8% of IgG treated mice as control). These results are 
in keeping with our previous studies and concur with the 
proposed angiogenic role of HGF in cancers [14]. These 
data also support our previously published in vitro results, 
which demonstrated that HGF inhibition (using AMG102) 
directly reduced proliferation and migration of human 
microvascular endothelial cells, HMEC-1 [19]. However, 
c-MET inhibition alone or in combination with AMG102 
did not affect CD31 expression (91 ± 6.2% and 87.6 ± 
7% respectively). Gemcitabine treatment as a single agent 
or in dual or triple combination also did not result in any 
significant changes in CD31 expression (88.3 ± 7.4%, 95.5 
± 5%, 96 ± 6.4% and 89 ± 6% respectively).  
In vitro studies
Role of HGF/c-MET in PSC-PC cell interactions in vitro
The role of the HGF/c-MET pathway in PSC-cancer 
cell interactions was determined by performing indirect 
co-culture experiments and assessing the effects of PSC 
secretions on cancer cell functions in the presence or 
absence of HGF/c-MET inhibitors and/or gemcitabine. 
i) Effect of HGF/c-MET inhibition ± gemcitabine on 
cancer cell proliferation in vitro
hPSC secretions with known amounts of HGF 
(2000pg/mL) induced AsPC-1 proliferation compared to 
controls i.e. cancer cells incubated with co-culture medium 
alone, confirming our previously published studies [14, 28]. 
This hPSC-induced cancer cell proliferation was unchanged 
by exposure of cells to hPSC secretions pre-treated with 
AMG102 or when cancer cells were treated with c-MET 
inhibitor alone. However, hPSC-induced cancer cell 
proliferation was significantly inhibited by the combination 
of AMG102+c-MET inhibitor. Gemcitabine alone and in 
dual combinations also significantly reduced cancer cell 
proliferation. The greatest reduction in hPSC-induced 
AsPC-1 proliferation was observed with triple therapy (HGF 
inhibition + c-MET inhibition + gemcitabine) (Figure 7A).
ii) Effect of HGF/c-MET inhibition ± gemcitabine on 
cancer migration in vitro
AsPC-1 cell migration was induced upon exposure 
to hPSC secretions, in agreement with our previously 
published reports [14, 28]. This induction of AsPC-1 
migration was prevented by each of the treatments with 
the greatest reduction observed in AsPC1 cells exposed to 
the triple treatment (HGF inhibition + c-MET inhibition + 
gemcitabine) (Figure 7B).
iii) Effect of HGF/c-MET inhibition ± gemcitabine on 
cancer cell apoptosis in vitro
For these studies, AsPC-1 cells were first subjected 
to serum starvation to induce apoptosis of the cells. In 
the presence of IgG treated hPSC secretions, AsPC-1 
apoptosis induced by serum starvation was inhibited 
albeit to a modest level (94 ± 1% of medium control). 
However there was no effect on such apoptosis with 
HGF inhibition alone, gemcitabine alone or in their dual 
combination. Interestingly, AsPC1 apoptosis induced by 
serum starvation was modestly but significantly increased 
further in the presence of c-MET inhibition as a single agent 
or in dual combination with AMG102 or with gemcitabine 
(111 ± 2.5%, 108 ± 1.8%, 110 ± 3.5% of medium control 
respectively). Importantly, this pro-apoptotic effect persisted 
in cells treated with the triple combination (105.3 ± 2%).
iv) Signalling pathways mediating the effects of HGF/c-
MET inhibition on cancer cells
To determine the effects of HGF/c-MET inhibition, 
c-MET phosphorylation and total c-MET were examined 
by immunoblotting. AsPC-1 cells were exposed to i) hPSC 
secretions pretreated with IgG (control) or with AMG102 
(HGF antibody) and ii) hPSC secretions in the presence 
of PHA665752 (c-MET inhibitor). Immunoblotting 
showed increased phosphorylated c-MET as well as total 
Table 1: Metastatic nodules noted in number of mice treated in our orthotopic model in various 
sites (n = 7 mice/group)
IgG A G C C+A A+G C+ G C+A+G
Liver 7 2 6 3 2 5 6 1
Kidney 4 0 2 1 1 3 3 0
Bowel 7 2 3 1 2 4 3 0
Retro-peritoneum 7 2 3 1 2 2 4 0
Diaphragm 6 1 2 1 2 3 2 0
TOTAL 31 7 16 7 9 17 18 1
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Figure 3: Effect of treatments on cancer cell density. (A) Representative images of primary tumor sections immunostained for the 
cancer cell marker cytokeratin (scale bar: 50 µm). (B) A bar graph depicting morphometric analysis for cancer cell density [calculated as 
the number of brown stained cells per unit area of tumor, and expressed as % of control (IgG treated) tumors]. Compared to the IgG treated 
group, cancer cell density was significantly reduced in mice treated with gemcitabine singly and in dual or triple combinations (*p < 0.05 vs 
IgG, n = 7 mice/group), while AMG102 and compound-A as single and dual combinations failed to decrease cancer cell numbers compared 
to IgG controls. Study Groups: Control group (IgG/vehicle control). AMG102 - A, Compound-A (small molecule c-MET inhibitor)- C, 
Gemcitabine - G, AMG102 + Compound-A (A+C), AMG102 + gemcitabine (A+G), c-MET inhibitor + gemcitabine (C+G), AMG102 + 
c-MET inhibitor + gemcitabine (Triple therapy or CAG)
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Figure 4: Effect of treatments on collagen deposition. (A) Representative images of tumor sections stained for Sirius red (marker 
for collagen deposition) (scale bar: 200 µm). (B) A bar graph depicting the morphometric analysis for collagen deposition in our orthotopic 
model. Fibrillar collagen deposition was increased in animals treated with gemcitabine + AMG102 when compared to any other treatment 
(*p < 0.05 vs IgG, AMG102 and compound-A). Study Groups: Control group (IgG/vehicle control). AMG102 - A, Compound-A (small 
molecule c-MET inhibitor)- C, Gemcitabine - G, AMG102 + Compound-A (A+C), AMG102 + gemcitabine (A+G), c-MET inhibitor + 
gemcitabine (C+G), AMG102 + c-MET inhibitor + gemcitabine (Triple therapy or CAG)
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Figure 5: Effect of treatments on DCLK1 (stem cell marker) expression. (A) Representative images of tumor sections 
immunostained for the stem cell marker DCLK1. Arrows indicate representative positive cells. (scale bar: 100 µm). (B) Graph depicting 
morphometric analysis for DCLK1 positive cells (number of brown positive cells per HPF, and expressed as % of control, IgG treated 
tumors). Compared to IgG treated tumors, there is a trend towards an increased number of cells expressing DCLK1 in gemcitabine treated 
mice when used as a single agent (G) or in combination with AMG102 (A+G). However this increase did not reach statistical significance. 
Notably, there is a significant reduction in expression of DCLK1 in tumors of mice treated with triple therapy when compared with other 
treatment involving gemcitabine as well as compound-A as single agent (*p < 0.02 vs G, A+G, C+G, C; n = 7 mice/group). Study Groups: 
Control group (IgG/vehicle control). AMG102 - A, Compound-A (small molecule c-MET inhibitor)- C, Gemcitabine - G, AMG102 + 
Compound-A (A+C), AMG102 + gemcitabine (A+G), c-MET inhibitor + gemcitabine (C+G), AMG102 + c-MET inhibitor + gemcitabine 
(Triple therapy or CAG)
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Figure 6: Effect of treatments on epithelial-mesenchymal transition (EMT). (A) Effect of treatments on TWIST (EMT marker) 
expression  (i) Representative images of tumor sections immunostained for the EMT marker TWIST. Arrows indicate representative 
positive cells. (scale bar: 100 µm). (ii) Graph depicting morphometric analysis for TWIST positive cells (EMT marker) [number of brown 
positive cells per unit area of tumor, and expressed as % of control (IgG treated tumors)]. Compared to IgG treated tumors, the number of 
cells undergoing EMT was significantly increased by gemcitabine treatment both as a single agent (G) and in combination with AMG102 
(A+G). Gemcitabine alone and in combination with compound-A as well as in triple therapy increased EMT when compared to AMG102 
treated tumors (*p < 0.05 vs IgG, §p < 0.05 vs AMG102, n = 7 mice/group). (B) Effect of treatments on E-cadherin (EMT marker) 
expression. (i) Representative immunoblots for e-cadherin (top panel) in tumor homogenates from the orthotopic model. The bottom 
panel shows immunoblots for total ERK, used as a loading control. (ii) Bar graphs showing densitometry results [corrected for respective 
loading controls and expressed as % of control in log10 scale (IgG treated tumors)]. Compared to control tumors, expression of e-cadherin 
is significantly reduced in mice treated with C+G. However this reduction is not seen in tumors from mice that received triple therapy 
(*§p < 0.05 vs A, A+C, CAG, n = 7 mice/ treatment group).Study Groups: Control group (IgG/vehicle control). AMG102 - A, Compound-A 
(small molecule c-MET inhibitor)- C, Gemcitabine - G, AMG102 + Compound-A (A+C), AMG102 + gemcitabine (A+G), c-MET inhibitor 
+ gemcitabine (C+G), AMG102 + c-MET inhibitor + gemcitabine (Triple therapy or CAG).
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c-MET in cancer cells exposed to hPSC secretions for 
10 minutes. Phosphorylation of cMET was significantly 
reduced by c-MET inhibitor but not by HGF inhibition 
(Figure 8A), while expression of total c-MET did not 
show any significant reduction with either AMG102 or 
c-MET inhibitor.
Downstream ERK1/2 activation was also examined 
by immunoblotting. Increased phosphorylation of ERK 
was observed in cancer cells exposed to hPSC secretions 
for 15 minutes. This effect was reversed in the presence 
of the HGF antibody as well as the c-MET inhibitor 
(Figure 8B). 
Figure 7: Effect of treatments on cancer cell proliferation and migration. (A) Effect on cancer cell proliferation in response to 
treatment with HGF inhibitor AMG102 (A), c-MET inhibitor (C) or gemcitabine (G), alone or in dual or triple combination in vitro. AsPC-
1 cells were incubated with medium control or IgG treated hPSC secretions, or hPSC secretions pre-treated either with AMG102, or c-MET 
inhibitor, or gemcitabine as single agents, or in dual or triple combinations. Compared to control, hPSC secretions (IgG group) significantly 
induced AsPC-1 proliferation (*p < 0.0001 vs medium control). This hPSC-induced AsPC-1 proliferation remained unchanged with either 
HGF (A) or c-MET inhibition (C) alone; but significantly inhibited with gemcitabine (G) as single agent and in any other combination 
(§p < 0.02 vs IgG). Similar reduction was also observed with HGF and c-MET inhibition as a dual combination (§p < 0.02 vs IgG). 
However, the greatest reduction was observed with triple therapy (C+A+G) in the treatment (**p < 0.0001 vs IgG; n = 5 separate hPSC 
preparations). (B) Effect on cancer cell migration in response to treatment with HGF inhibitor AMG102 (A), c-MET inhibitor (C) or 
gemcitabine (G), alone or in dual or triple combination in vitro. AsPC-1 cells were incubated with medium control or IgG treated hPSC 
secretions, or hPSC secretions pre-treated either with AMG102, or c-MET inhibitor, or gemcitabine as single agents, or in dual or triple 
combinations. Compared to medium control, hPSC secretions (IgG group) significantly induced AsPC-1 migration (§p < 0.0001 vs medium 




Using both in vivo and in vitro approaches, this 
study has provided novel evidence to indicate that 
stromal reprogramming (by inhibiting the HGF/c-MET 
pathway) combined with chemotherapy significantly 
reduces pancreatic cancer progression. The most effective 
combination was ‘triple therapy’ comprising a standard 
chemotherapeutic agent (gemcitabine), a monoclonal 
antibody against human HGF (AMG102) and a c-MET 
inhibitor. This triple therapy induced significantly greater 
reduction in tumor volume compared to single and dual 
treatments and importantly, virtually eliminated metastasis 
in our orthotopic model of pancreatic cancer. Our in vivo 
findings with triple therapy were supported by the results 
of our in vitro experiments showing that triple combination 
inhibited both cancer cell proliferation and migration to a 
greater extent than other treatment combinations.
Both HGF inhibition and c-MET blockade (using 
the small molecule c-MET inhibitor Compound-A) alone 
resulted in tumor reduction to a similar extent as that 
observed with gemcitabine. Supporting these results, 
are our in vitro observations whereby HGF inhibition or 
c-MET blockade alone inhibited cancer cell proliferation. 
However, dual combinations i.e HGF inhibition + c-MET 
blockade, HGF inhibition + gemcitabine and c-MET 
blockade + gemcitabine did not exhibit any additive effect 
in terms of tumor reduction. Our findings with c-MET 
blockade + gemcitabine do not agree with studies that 
have reported a synergistic effect between inhibition of 
c-MET and gemcitabine [22, 29, 30]. Notably, none of 
these studies have considered the role of stromal cells in 
their preclinical cancer models. The most recent of these 
studies [29] has employed both syngeneic and xenogeneic 
orthotopic models to demonstrate the effects of c-MET 
inhibition in combination with gemcitabine: However 
the stromal cells employed for their in vitro studies 
were limited to endothelial cells and vascular smooth 
muscle cells, and lacked the predominant source of HGF 
i.e. PSCs. The discrepancy between the results of these 
studies and our data suggests that in the presence of a 
continuous source of HGF secretion (i.e. PSCs) as in our 
study, c-MET inhibition alone may not be sufficient to 
significantly reduce cancer progression. 
The observed reduction in tumor volumes in 
treated mice could be a result of reduced cancer cell 
proliferation as well as increased apoptosis. In our in 
vitro experiments, serum starvation induced apoptosis in 
cancer cells; however in the presence of hPSC secretions 
this effect was inhibited and may explain the increased 
tumor volumes observed in IgG treated mice in vivo. 
However, gemcitabine and HGF inhibition alone or in dual 
combination did not influence cancer cell apoptosis; hence 
the reduced tumor volumes in these mice could be due 
to reduced proliferation rather than increased apoptosis of 
cancer cells. Interestingly, c-MET inhibition as a single 
agent and in all other combinations exerted a pro-apoptotic 
effect which is in keeping with similar published reports in 
other cancers [31–33]. This could be one of the mechanisms 
mediating the observed reduction in tumor volume observed 
with c-MET inhibition in our in vivo model. 
With respect to fibrosis, tumors from mice that 
received gemcitabine treatment as a dual combination with 
HGF inhibition exhibited higher fibrosis compared to all 
other groups confirming our previous results [14]. Tumors 
from other mice that received gemcitabine also showed a 
trend towards increased (albeit not statistically significant) 
fibrosis. This could possibly be due to the increased 
activation state of PSCs in response to the factors released 
by gemcitabine affected cancer cells [14].
Several studies have linked activation of c-MET 
signalling to phosphorylation of intracellular signalling 
cascades such as PI3K/AKT, MAPK/ERK [34, 35] or 
FAK [36] in pancreatic cancer models, leading to tumor 
cell invasiveness, motility and resistance to gemcitabine 
therapy. In the current study, we observed that the effect of 
c-MET inhibition resulted in downregulation of ERK1/2 
signalling, which concurs with our previous observation 
with HGF inhibition [14]. Effects of Akt signalling 
were not investigated as hPSC secretions did not induce 
phosphorylation of Akt as we previously reported [14]. 
Cancer cells exposed to hPSC secretions exhibited 
increased activation/phosphorylation of c-MET most 
likely in response to HGF in the secretions. As expected, 
this c-MET phosphorylation was prevented in the presence 
of the c-MET inhibitor PHA665752, as previously 
reported [32, 33, 37–39].
Regarding metastatic spread in our model, a 
significant reduction in metastasis was observed with 
c-MET inhibition as a single agent, as well as in dual 
combination with AMG102. However this anti-metastatic 
effect was lost when c-MET inhibition was combined with 
gemcitabine treatment. These observations are similar to 
our previous findings [14], where the anti-metastatic effect 
of AMG102 was lost when combined with gemcitabine. 
Taken together these observations strengthen our view 
[14], that gemcitabine selects out a population of cancer 
cells with enhanced survivability and migratory potential. 
We examined this concept by assessing orthotopic tumors 
for the expression of the stem cell marker double cortin 
like kinase-1(DCLK1), which is known to be elevated in 
PC and is associated with increased metastatic potential of 
the disease [40, 41] and the EMT marker TWIST. 
While HGF/c-MET inhibition itself did not affect 
stemness or EMT, gemcitabine treatment alone as well as 
in combination with AMG102 or c-MET inhibitor induced 
both stemness as well as EMT as evidenced by increased 
expression of DCLK1 and TWIST, and reduced e-cadherin 
expression in the tumors. These observations support our 
previous findings [14] as well as others that indicate the 
formation of a chemo-resistant population of cancer cells 
following chemotherapy [23–25]. 
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Figure 8: Effect of treatments on cancer cell signalling. (A) Cancer cell response to HGF inhibition (AMG102) and c-MET 
inhibition (cMet Inh) was mediated by c-MET activation. (i) Representative immunoblots for phosphorylated (top panel) and total c-MET 
(middle panel) in AsPC-1 cell lysates collected after exposure of cells to hPSC secretions pretreated with either IgG or AMG102 or 
c-MET inhibitor (c-Met Inh) for 10 minutes. The bottom most panel shows GAPDH, used as a loading control. (ii) Bar graphs showing 
densitometry results [corrected for respective loading controls and expressed as % of control (co-culture medium)]. Compared to medium 
control, hPSC secretions significantly increased phospho-c-MET but not total c-MET (*p < 0.05, n = 3 hPSC preparations). This hPSC-
induced phosphorylation of c-MET was inhibited with AMG102 (§p < 0.02 vs Secr+IgG, n = 3 hPSC preparations) as well as c-MET 
inhibition (**p < 0.01 vs Secr+IgG, n = 3 hPSC preparations). (B) Cancer cell response to HGF inhibition (AMG102) and c-MET inhibition 
(cMet Inh) was mediated by ERK1/2 activation.  (i) Representative immunoblots for phosphorylated ERK1/2 and GAPDH in AsPC-1 
cell lysates collected after exposure of cells to hPSC secretions pretreated with either IgG or AMG102 or c-MET inhibitor (c-Met Inh) for 
15 minutes. The top panel shows phosphorylated ERK1/2 while the lower panel indicates GAPDH, used as a loading control. (ii) Graph 
showing densitometry results [calculated by correction for respective loading controls and expressed as % of control (co-culture medium)]. 
Compared to medium control, hPSC secretions significantly increased ERK1/2 phosphorylation (Secr+IgG; *p < 0.05 vs medium control). 
This hPSC-induced phosphorylation of ERK1/2 was inhibited with HGF inhibition and c-MET inhibition (§p < 0.01 vs Secr+IgG, n = 3 
secretions from separate hPSC preparations).
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Important observations in this model were 
made in the mice that received all three agents (triple 
therapy). The greatest reduction of tumor volume was 
noted in these mice when compared to IgG treated 
mice. Notably, metastasis was virtually eliminated in 
these mice. Striking inhibition of metastasis despite the 
presence of gemcitabine was surprising since as noted 
above, gemcitabine alone or in dual combinations did not 
prevent metastasis and actually increased the stemness 
and the migratory potential of cancer cells. In contrast, 
when gemcitabine was part of the triple therapy regimen, 
stemness of cancer cells in the pancreatic tumors was seen 
to be significantly reduced. 
With regard to EMT as assessed by e-cadherin 
expression, tumors of mice receiving gemcitabine as a 
single agent or in dual combination with HGF inhibition 
or c-MET inhibition exhibited reduction in e-cadherin 
expression, suggesting increased EMT. This concurs 
with the observed increase in metastasis in these groups. 
Interestingly pancreatic tumors of mice receiving triple 
therapy showed no such decrease in e-cadherin expression, 
suggesting that EMT was not increased in this group, thus 
supporting the observed absence of metastasis. However, 
this effect on EMT in the triple therapy group was not 
evident with another EMT marker, the transcription 
factor TWIST. The lack of an inhibitory effect on TWIST 
expression, despite the significant inhibition of metastasis, 
in these mice was unexpected. This observation raises the 
possibility that factors other than TWIST may regulate 
EMT in pancreatic cancer cells, warranting  future work 
in this area.
We postulate that the striking inhibitory effects of 
triple therapy on PC progression in our orthotopic model 
could be explained by a combination of effects that occur 
along the HGF/c-MET pathway. In untreated PC, stromal 
PSCs secrete HGF in its precursor form, which is activated 
by proteases such as urokinase plasminogen activator 
(uPA). Binding of HGF to its receptor c-MET on cancer 
cells stimulates several intracellular signalling cascades, 
which regulate cancer cell functions such as proliferation, 
migration and apoptosis. In addition, binding of HGF to 
c-MET increases production of uPA in cancer cells [42], 
which further activates precursor HGF to active HGF, thus 
forming a feed forward loop (Figure 9).
Three elements of triple therapy possibly inhibit 
several steps along the HGF/cMET pathway:
1) HGF inhibition neutralises PSC-derived active 
HGF in the ECM surrounding cancer cells, thus preventing 
HGF/c-MET binding. 2) c-MET inhibition blocks ligand-
receptor binding leading to. a) inhibition of downstream 
intracellular signalling cascades. b) reduction of uPA 
production by cancer cells, thus preventing further HGF 
activation (thus inhibiting the positive feedback loop).c) 
blockade of stemness in cancer cells (given that c-MET is 
recognized to be a stem cell marker in pancreatic cancer 
[30, 43]). d) blockade of the transactivation of the c-MET 
receptor that is known to occur via other pathways such as 
the epidermal growth factor receptor (EGFR) [44]. 
3) Gemcitabine, a nucleoside analogue, causes 
cancer cell death [45].
The overall outcome of the above effects is to inhibit 
the well-established bidirectional interaction between 
PSCs and cancer cells in addition to killing cancer 
cells, thereby resulting in decreased tumor growth and 
metastasis.
In summary our study indicates that a novel and 
an effective therapeutic approach to pancreatic cancer 
may be achieved with a two-pronged approach that 
targets not only cancer cells but also stromal cells to 
interrupt stromal-tumor interactions that facilitate cancer 
progression. To date, a number of targeted therapies that 
showed significant promise in pre-clinical studies have 
failed to translate successfully to the clinical situation 
[46–49]. We believe this is partly due to the absence of 
a stromal component in these pre-clinical models.  The 
use of a more biologically relevant model of pancreatic 
cancer involving both human pancreatic cancer cells and 
human pancreatic stellate cells increases the potential for 
our results to be translated to the clinical situation.
MATERIALS AND METHODS 
Reagents
Reagents include Iscove’s Modified Dulbecco’s 
Medium, RePMI Medium 1640, fetal bovine serum, 
glutamine, and 4,6-diamidino-2-phenylindole (DAPI) 
from (Life Technologies Corporation, Tullamarine, 
VIC, Australia); Dulbecco’s Modified Eagle’s Medium 
and Xten Hybricell SFM Medium from Thermo Fisher 
Scientific (Waltham, MA, USA); anti–human alpha 
smooth muscle actin (αSMA) antibody, anti-human 
DCLK1 antibody, from Sigma-Aldrich (St. Louis, 
MO, USA); anti-human cytokeratin antibody, 3,3–
diaminobenzidine (DAB) tetrahydrochloride substrate 
from DAKO (Campbellfield, VIC, Australia); anti-
human CD31 antibody, anti-human TWIST antibody 
from Abcam (Melbourne, VIC, Australia) and anti- 
human glial fibrillary acidic protein (GFAP) antibody 
(Millipore, North Ryde, NSW, Australia); Safil 5/0 
polyglycolic acid absorbable surgical suture from B. 
Braun (BellaVista, NSW, Australia); Cell culture inserts 
8µM pores (Becton-Dickinson, Bedford, MA, USA); 
CytoSelect Tumor Transendothelial Migration Assay 
kit from Cell Biolabs, Inc. (San Diego, CA, USA); 
Cell Counting Kit-8 (Dojindo Technologies Pty Ltd, 
Parkville, VIC, Australia) multi-parameter apoptosis kit 
from Cayman chemicals, (Ann Arbor, MI, USA) Pierce 
Bicinchoninic Acid (BCA) protein assay kit (Thermo 
Fisher Scientific Pty Ltd, Scoresby, VIC, Australia). 
HGF neutralizing antibody, (AMG102/ Rilotumumab) 
and small molecule inhibitor for c-MET (Compound-A) 
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from Amgen Inc. (Amgen Inc., Thousand Oaks, CA, 
USA), gemcitabine as gemcitabine hydrochloride 
from Hospira (Mulgrave, VIC, Australia), and c-MET 
inhibitor 100nM (PHA665752, Tocris Bioscience, 
Noble Park, VIC, Australia) were used. Antibodies for 
anti-e-cadherin (Abcam, Melbourne, VIC, Australia), 
anti-human phospho-p44/42 MAPK (ERK1/2) and total 
ERK1/2 (Cell Signaling Technology, Danvers, MA, 
USA) were used.
Orthotopic model of pancreatic cancer (in vivo 
studies)
The orthotopic model used for these studies has 
been described in detail previously [7, 10, 14, 50]. Briefly, 
6–8 week old female athymic nude mice (BALBc nu/nu) 
were anaesthetized and an incision made in the left flank 
followed by exteriorization of the spleen and tail of the 
pancreas. A mixture of human PC cells (AsPC-1) 1 × 106 
+ human PSCs 1 × 106 in 50 μL PBS was injected into the 
tail of pancreas. This ratio of PC cells to PSCs was chosen 
to replicate early cancer development and progression. 
Seven days after implantation of AsPC1+hPSCs, mice 
were randomized to receive treatment as detailed below 
for a further 6 weeks. 
Animal grouping (n = 7 mice/group)
Group 1 Control group (IgG/vehicle control). 200 μl PBS 
with isotype IgG twice weekly intraperitoneal (IP) injections 
and daily oral gavage of soybean oil as vehicle control for 
Compound-A (small molecule inhibitor for human c-MET) 
(Group referred to in figures as “IgG”) Group 2 AMG102 
(monoclonal antibody against human HGF) dissolved in 200  μl 
PBS 300 μg IP twice weekly; dose based on our previously 
published studies [14, 18]. (Group referred to in figures as “A”) 
Group 3 Compound-A (small molecule c-MET inhibitor) 
60 mg/kg BW dissolved in soybean oil administered as daily 
oral gavage; dose based on preliminary dose-response studies 
establishing the maximally effective and non-toxic dose. 
(Group referred to in figures as “C”) Group 4 Gemcitabine 
75 mg/kg BW IP twice weekly (Group referred to in figures 
as “G”) Group 5 AMG102 + Compound-A (A+C) Group 6 
AMG102 + gemcitabine (A+G) Group 7 c-MET inhibitor + 
gemcitabine (C+G) Group 8 AMG102 + c-MET inhibitor + 
gemcitabine (Triple therapy or CAG).
Pancreatic tumor growth was monitored by palpation. 
Mice were sacrificed after six weeks of treatment. Primary 
tumors were resected and their size measured using digital 
Vernier callipers by two separate observers. Tumor volume 
was calculated to two decimal points, according to an 
Figure 9: Schematic depicting the possible mechanisms involved in effects of triple therapy on PC progression. Possible 
actions of these compounds are shown as numbered red crosses in the figure. 1. AMG102 neutralizes active HGF, reducing HGF/c-
MET binding. 2. c-MET inhibitor works by preventing binding of ligand HGF to the receptor c-MET directly by inhibiting the pathway. 
Additionally, c-MET inhibitor acts by:  2a) Reducing uPA production by cancer cells. 2b) Inhibiting further HGF activation. 2c) Preventing 
transactivation of c-MET by other pathways such as EGFR. 3. Gemcitabine causes cancer cell death. 4. Overall the bidirectional interactions 
between PSCs and cancer cells are significantly reduced.
Oncotarget76735www.impactjournals.com/oncotarget
established formula [1/2 (length x breadth x width) [51]. 
Tumor tissue was then dissected out for further processing. 
The abdominal cavity, mesentery, spleen, liver and lungs 
were examined and scored according to the presence or 
absence of visible metastatic nodules. Metastatic nodules 
were collected, fixed in formalin and processed for H&E 
staining. Tumors were compared with respect to size and 
weight. Tumors were stained with H&E for morphology, 
while collagen deposition was assessed by Sirius red 
staining as described previously [10, 28]. Primary tumor 
sections were also immunostained for cytokeratin (cancer 
cell marker), DCLK1 (stem cell marker), TWIST (EMT 
marker), and CD31 (endothelial cell marker). 
Expression of αSMA, cytokeratin, CD31, 
DCLK1 & TWIST in primary tumors
Paraffin sections (4 µm thickness) of primary tumors 
were dewaxed and rehydrated. Following heat-mediated 
antigen retrieval, tumor sections were incubated overnight 
at 4oC with respective primary antibodies as described 
previously [14]. Immunostaining of tumor sections for 
αSMA (1:800), cytokeratin (1:75), CD31 (1:50), DCLK1 
(1:500), and TWIST (1:500) were performed using 
anti-human primary antibodies in provided dilutions 
in blocking buffer. This was followed by incubation 
with respective HRP-labelled secondary antibodies. 
Subsequently, the sections were incubated with DAB 
substrate and the signal was visualized by chromogen.
For morphometric analyses, ten fields were selected 
randomly (by observers blinded to treatment groups) for 
each tissue section and positive stained (brown) cells were 
counted, as described previously [14, 28]. Endothelial 
cells in primary tumors were identified by immunostaining 
for the endothelial cell marker CD31. Cells expressing 
stem cells and EMT characteristics were assessed by 
immunostaining the tumor sections for stem cell marker 
DCLK1 and transcription factor TWIST respectively. 
Results were analysed as the total number of positive cells 
in all 10 selected fields and expressed as % of control (i.e. 
tumor sections from IgG treated mice).
Immunoblotting on tumor homogenates
Tumor samples that were snap frozen were 
homogenized by mechanical disruption using a mortar 
and pestle in presence of liquid nitrogen in RIPA buffer 
with protease and phosphatase inhibitors. Proteins were 
quantified using bicinchoninic acid assay (BCA assay) 
according to Manufacturer’s instructions. Homogenates 
were then subjected to immunoblotting as detailed below 
for assessment of e-cadherin expression.
Proteins were separated using 10% SDS 
polyacrylamide gels and transferred onto nitrocellulose 
membranes. Membranes were blocked for one hour in 5% 
skim milk in TRIS buffered saline with Tween-20 (TTBS), 
followed by overnight incubation at 4˚C anti-rabbit 
e-cadherin 1:500. Following a wash protocol, membranes 
were incubated for one hour at room temperature 
with an HRP-conjugated goat anti-rabbit secondary 
antibody (DAKO Australia Pty Ltd, Kingsgrove, NSW, 
Australia), diluted 1:2000 in blocking buffer. Target 
proteins were detected using the Bio-Rad ECL kit (Bio-
Rad, Philadelphia, PA, USA) as described previously 
[14]. Loading control total ERK1/2 was determined by 
incubating overnight at 4oC with anti-rabbit ERK1/2 
antibody (Cell Signaling Technology, Danvers, MA, 
USA) diluted 1:1000 in TTBS. Densitometry readings 
for e-cadherin were corrected to their respective loading 
controls. Results are expressed as % of control (i.e. tumor 
homogenates from IgG treated tumors).
In vitro studies: cell culture
AsPC1 cells were cultured and hPSCs were isolated 
and cultured as previously published by us [14].
Indirect co-culture experiments
To study the role of the HGF/c-MET pathway in 
the interactions between PSCs and cancer cells in vitro, 
indirect co-cultures were set up which involved incubation 
of cancer cells with conditioned medium from PSCs.
Collection of conditioned medium from PSCs 
and HGF measurement
As described previously, PSCs were passaged 
by trypsinization when 70–80% confluence was 
reached. Conditioned media (hPSC secretions) used for 
experiments were collected from hPSCs. Media (0.1% 
SFM4MAb for proliferation and migration assays or 0% 
IMDM for apoptosis assays) were collected, centrifuged 
at 1,000g for 10 min at 4°C, and the supernatant was 
concentrated with Centricon YM3 filters (Millipore). 
HGF in hPSC secretions was quantified using a human 
HGF Quantikine ELISA Kit (R&D Systems) according 
to the manufacturer’s instructions as described previously 
[19]. The secretions were stored at –80°C until used for 
functional assays. For assays that required pretreated 
secretions, appropriate dilution of secretions was 
performed with co-culture medium so as to standardize 
HGF to a concentration of 2000pg HGF/ml. This 
concentration was used since it reflects the actual amount 
produced by hPSCs over 24 hours [14, 19]. 
Pretreatmeant of hPSC secretions and cancer cells
Secretions from hPSCs (n = 5) that had been 
standardized to 2000 pg HGF/mL were pretreated for 
one hour at 37oC with either 60 µg/mL AMG102 (HGF 
neutralizing antibody) or 60 µg/mL IgG (isotype control 
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for AMG102). Similarly cancer cells were pre-exposed to 
the c-MET inhibitor 100 nM (PHA665752) for one hour 
at 37oC. Following this pretreatment of cancer cells, hPSC 
secretions ±  gemcitabine (300 µg/mL) were added to the 
cells. Therefore the experimental set up included cancer 
cells treated with PSC secretions in presence and absence 
of either AMG102 or c-MET inhibitor or gemcitabine.
The concentrations of HGF antibody, c-MET 
inhibitor and gemcitabine were calculated to correspond 
to the in vivo doses used in these studies, assuming the 
total circulating volume of a 20 gm mouse to be 5mL as 
reported in our previous publication [14].
Note: For our in vitro studies a commercially 
available c-MET inhibitor (PHA665752) that has been 
widely used in published literature was employed [37, 38] 
since it is water soluble. Compound-A used in our in vivo 
model, is soluble only in soybean oil and therefore could 
not be used in culture medium.
Proliferation of AsPC-1 cells in response to 
indirect co-culture
The effects of HGF inhibition on AsPC-1 
proliferation were measured using the Cell Counting 
Kit-8. AsPC-1 cells were seeded at a density of 5000 cells/
well in a 96 well plate. The following day, culture medium 
was removed and wells were rinsed twice with warm PBS. 
200 µL of pretreated hPSC secretions (see above) were 
applied to each well. After incubation for 24 hours at 37°C 
the assay was performed according to Manufacturer’s 
instructions. This assay uses a tetrazolium salt, which 
produces a water-soluble formazan when reduced. The 
amount of formazan produced is directly proportional to 
the number of living cells. The optical density of the wells 
was determined at 450 nm.
Migration of AsPC-1 cells in response to indirect 
co-culture
AsPC-1 cell migration was assessed using a 
modified Boyden chamber method as published by our 
Group previously [10, 52] according to Manufacturer’s 
instructions. Number of migrated cancer cells was 
assessed by recording fluorescence (480 nm/520 nm) on 
the plate using a SpectraMax M2e micro plate reader 
(Molecular Devices, Sunnyvale, CA, USA). 
Apoptosis of AsPC-1 cells in response to indirect 
co-culture
AsPC-1 cells were seeded at a density of 15,000 
cells/well in a 96-well opaque plate and cultured in serum-
free IMDM overnight to induce apoptosis. Cells were then 
incubated with hPSC secretions (pre-treated as described 
above) for 24 hours and apoptosis was assessed by 
staining for cell based Annexin–V tagged with FITC as per 
the Multi-parameter Apoptosis Kit instructions (Cayman 
Chemicals, Ann Arbor, MI, USA). Apoptosis was assessed 
by recording fluorescence (485 nm/535 nm) on the plate 
using a SpectraMax M2e micro plate reader (Molecular 
Devices, Sunnyvale, CA, USA). 
Immunoblotting for signalling pathways (c-MET 
phosphorylation and MAPK activation)
AsPC-1 cells were exposed to one of the following 
treatments for 15 minutes: i) co-culture medium; ii) 
hPSC secretions + IgG; iii) hPSC secretions + AMG102, 
iv) hPSC secretions + c-MET inhibitor (as described 
above, using secretions from n = 3 different hPSCs 
preparations). After 15 minutes exposure, secretions 
were removed, cells were lysed and protein quantified 
using bicinchoninic acid assay (BCA assay) according to 
Manufacturer’s instructions. Lysates were then subjected 
to immunoblotting as detailed below for assessment of 
MAPK activation. Similarly lysates from AsPC-1 cells 
were collected for assessment of c-MET activation after 
treatment for 10 minutes.
Lysed proteins were separated using 10% SDS 
polyacrylamide gels and transferred onto nitrocellulose 
membranes. Membranes were blocked for one hour in 
5% skim milk in TRIS buffered saline with Tween-20 
(TTBS), followed by overnight incubation at 4°C 
anti-rabbit phospho-MET (Tyr1234/1235) (D26, Cell 
Signaling Technology, Danvers, MA, USA) 1:1000, anti-
rabbit total MET (D1C2, Cell Signaling Technology, 
Danvers, MA, USA) 1:1000 and anti-mouse GAPDH 
(Abcam, Melbourne, VIC, Australia) 1:50000. Overnight 
incubation with phospho-p44/42 MAPK (ERK1/2) (Cell 
Signaling Technology, Danvers, MA, USA) rabbit mAb 
diluted 1:1000 in TTBS with 5% BSA (bovine serum 
albumin) was performed to determine MAPK activation. 
Following a wash, membranes were incubated for one 
hour at room temperature with an HRP-conjugated goat 
anti-rabbit secondary antibody (DAKO Australia Pty Ltd, 
Kingsgrove, NSW, Australia), diluted 1:2000 in blocking 
buffer. Target proteins were detected using the Bio-Rad 
ECL kit (Bio-Rad, Philadelphia, PA, USA) as described 
previously [14]. Loading control GAPDH was determined 
by incubating overnight at 4oC with anti-mouse 
GAPDH antibody (Abcam, Melbourne, VIC, Australia) 
diluted 1:50000 in TTBS. Densitometry readings for 
phosphorylated ERK1/2 and c-MET were corrected for 
their loading controls. Results are expressed as % of 
control (i.e. expression in cells treated with coculture 
medium as control).
Statistical analysis
Data are expressed as mean ± SEM. Student’s t-test, 
one-way analysis of variance with Tukey’s post hoc test, or 
Fisher’s exact tests were applied as appropriate. Analyses 
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were performed using GraphPad Prism 6.00 for Mac OS 
X (GraphPad Software, San Diego, CA, USA).
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